Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 85(7) – July 2025; Article No. 08, Pages: 53-61 **DOI:** 10.47583/ijpsrr.2025.v85i07.008

Review Article

Nanoparticles as Advanced Drug Delivery Systems: Innovations, Mechanisms, and Pharmaceutical Applications: A Review

Shivam Dhole*, Shrikrishna Baokar, Rajendra Patil
Delonix Society's Baramati College of Pharmacy, Barhanpur, Baramati, Dist Pune, Maharashtra, India 413102.
***Corresponding author's E-mail:** shivamdhole414@gmail.com

Received: 14-03-2025; **Revised:** 18-06-2025; **Accepted:** 26-06-2025; **Published online:** 15-07-2025.

ABSTRACT

Nanoparticles are revolutionizing the delivery of pharmaceutical drugs by providing creative answers to some of the most significant problems with conventional treatments, including inadequate bioavailability, poor water solubility, and lack of tailored delivery. These microscopic carriers contribute to increased therapeutic efficacy and decreased undesirable side effects by permitting controlled and site-specific medication release. For drug delivery, a large range of nanoparticle types have been investigated, including dendrimers, metallic particles, polymeric nanoparticles, lipid-based systems, and carbon- based nanostructures. Treatments for diseases including cancer, neurological disorders, and infectious diseases have already showed promise due to their special capacity to penetrate biological barriers and interact with particular cells in a targeted manner. The classification, manufacturing, and functionality of these nanoparticles when they are loaded with medicinal compounds are all examined in further detail in this paper. It also discusses significant safety and regulatory issues, as well as their present medical use, including formulations that have FDA approval. Lastly, it examines fascinating new discoveries that are advancing our understanding of genuinely customized treatment alternatives, such as multifunctional nanoparticles and the application of artificial intelligence in the creation of next-generation nanomedicines.

Keywords: Nanoparticles, Drug delivery, Targeted therapy, Controlled release, pharmaceutical nanotechnology, Biocompatibility, FDA-approved nanomedicines.

INTRODUCTION

A drug's efficiency is determined by its ability to reach its intended location in the body and remain there long enough to perform its function without endangering other parts of the body, in addition to its potency. Regretfully, there are shortcomings in many traditional drug administration techniques. The following problems can result in less effective therapies, more frequent dosing, and a higher risk of adverse effects: poor water solubility, rapid evacuation from the body, breakdown in the bloodstream, and lack of targeting [1].

Nanotechnology is significantly changing this area. More sophisticated drug delivery methods have been created by scientists using nanoparticles, which are microscopic particles with sizes ranging from 1 to 1000 nanometers. Unlike most medications, these particles can even cross biological barriers due to their unique properties, such as their vast surface area and customisable surfaces [2]. These characteristics enable nanoparticles to deliver a broad range of treatments straight to the site of action, including proteins, genetic material, and compounds that are difficult to dissolve [3].

Types of Nanoparticles in Drug Delivery

Nanoparticles are used in pharmaceutical medication administration in a variety of ways, each having a unique structure and composition to meet a particular medical requirement. These small carriers offer varying benefits in terms of medication delivery, depending on their construction and composition. Some are excellent for delivering complex medicines, while others are excellent for targeting certain cells and maintaining stability. Lipid-based, polymeric, dendritic, metallic, micellar, and carbon-based nanoparticles are the primary varieties; each has unique advantages in enhancing the way medications function in the body.

Lipid-Based Nanoparticles

A Lipid-Based Nanoparticle Structure Made from layers of fats known as phospholipids, liposomes are small, bubble-like structures with a watery core. Their capacity to transport both fat-loving (lipophilic) and water-loving (hydrophilic) medications is what makes them unique and incredibly adaptable. They are also safe for the body because they are normally well-tolerated, decompose spontaneously, and don't trigger immunological reactions.

Doxil, a version of the chemotherapeutic medication doxorubicin encased in a protective liposome covering, was the first FDA-approved nanodrug, demonstrating the significant impact liposomes have already had in the treatment of cancer [4].

Polymeric Nanoparticles

Nanoparticles of polymers small drug carriers known as polymeric nanoparticles are created from substances known as polymers, which might be synthetic or natural. PLGA is a widely used polymer that is safe, biodegradable, and even FDA-approved. The ability to distribute medication gradually and steadily over time makes it excellent [5]. Chitosan is another beneficial polymer that is derived from natural sources. It is perfect for administering medications through the nose or mouth because of its sticky nature, which enables it to adhere to moist surfaces [6]. Scientists frequently use a technique known as PEGylation to coat these nanoparticles with polyethylene glycol (PEG) to increase their effectiveness. This prolongs the particles' circulation and prevents the immune system from eliminating them too soon.

Metallic Nanoparticles

Regarding their potential use in medicine, metallic nanoparticles are quite intriguing. Consider gold nanoparticles; their unique light-reaction properties make them ideal for applications such as photothermal therapy, a heat-based cancer treatment, and even medical imaging [7]. At low levels, they are also generally safe, stable, and simple to modify for various purposes. Another notable feature is that silver nanoparticles are excellent at eliminating germs. They are therefore frequently found in creams or dressings for wounds in order to help prevent infections and promote healing [8]. There are also magnetic iron oxide nanoparticles. Because of this, they are extremely helpful for directing medications to the proper location in the body utilizing magnets and for obtaining more crisp MRI scan images [9].

Dendrimers and Micelles

Extremely small, tree-shaped molecules having a tidy, layered structure are called dendrimers. Similar to molecular balls, they have a core, branches, and several ends that can be customized. Because of their design, they are excellent for holding a lot of drugs and releasing it in a precise and regulated manner [10]. However, when specific kinds of molecules—molecules that contain both fat-loving and water-loving components—combine in water, micelles are created spontaneously. They form tiny structures that resemble bubbles and have a core that can contain medications that are greasy and water-resistant. As a result, those medications dissolve more readily in the body, do not clump together, and remain in the bloodstream for a longer period of time [11].

Carbon-Based Nanoparticles

Nanoparticles made of carbon are exhibiting great potential in the field of medicine. Tiny carbon nanotubes, which resemble tubes, can enter cells covertly and transport medications or genetic material to specific locations. It's quite amazing, but there are still some concerns about their safety, such as whether they could injure people or remain in the body for too long [12]. Afterwards, there are fullerenes, which resemble tiny balls of carbon more. These are being studied for carrying genes and medications, particularly for the treatment of brain disorders like Alzheimer's, and they have inherent antioxidant qualities [13].

Mechanisms of Drug Delivery via Nanoparticles

The ability of nanoparticles to carry, release, and deliver the medication precisely where it's needed determines how effectively they operate as drug delivery vehicles. These little devices provide a number of ingenious methods to improve the accuracy and efficiency of drug delivery. Certain nanoparticles use passive targeting, in which they spontaneously gather in particular locations, such as tumors. Some are made for active targeting, which locates and attaches to target cells utilizing particular chemicals. To ensure that the drug acts at the precise time and location, certain systems also release medications gradually over time or react to changes in the body's pH or temperature.

Passive Targeting (Enhanced Permeability and Retention Effect)

The enhanced permeability and retention (EPR) effect, which primarily occurs in malignancies and inflammatory tissues, is exploited by passive targeting. Because these regions frequently have poor drainage and leaky blood arteries, nanoparticles may enter and remain there for longer than they would in healthy tissue [14]. The precise size of the nanoparticles—typically between 10 and 200 nanometers—allows them to accumulate in certain areas and deliver additional medication precisely where it is required. This lessens adverse effects on the rest of the body while also improving the efficacy of the treatment.

Active Targeting (Ligand-Receptor Binding)

Drug delivery with nanoparticles is more intelligent and selective when active targeting is used. Using unique chemicals that can identify and bind to particular receptors present in large quantities on particular target cells, such as transferrin, folic acid, peptides, or antibodies, it decorates the surface of the nanoparticle [15]. Through a mechanism known as receptor-mediated endocytosis, the cell draws the nanoparticle inside after it has bound to the receptor. Folic acid-conjugated nanoparticles are an excellent illustration of this; they have proved successful in targeting cancer cells that overproduce folate receptors.

Controlled and Sustained Drug Release

Nanoparticles have the advantage of being able to be engineered to deliver medications gradually and consistently over time. Patients can reduce the frequency of their medication intake by using controlled or sustained release, which helps the drug remain at the ideal level in the body for longer [16]. A number of factors affect how the medication is released, including the size of the particles, the way the drug is packed inside, and the type of material employed (PLGA, for instance, degrades gradually over weeks). This type of distribution not only increases patient adherence to medication and lessens adverse effects, but it also makes therapy more convenient.

Stimuli-Responsive Drug Delivery

Stimulus-responsive, or "smart," nanoparticles are made to release their medications only in response to certain stimuli, which can be either internal or external. By controlling the drug's release time and location, this enhances accuracy and lessens adverse effects. pH levels have an effect on certain of these intelligent systems. For instance, when pH-sensitive nanoparticles reach tumors and specific cell compartments, which are more acidic than healthy tissues, the medications can be released [13]. Others react to temperature; for example, PNIPAM releases its medication when the area is lightly heated (around 42°C), which is particularly helpful when heat-based cancer treatments are being used.

Additionally, redox-responsive nanoparticles exist that capitalize on the elevated glutathione levels within cancer cells. Only in that environment can these particles degrade and release their drug [12]. Additionally, a few systems are stimulated by outside instruments such as light, magnets, or ultrasonic waves. These techniques have the ability to command the release of the drug at the precise location [17]. Together, these intelligent delivery methods are advancing precision and individualized medicine.

Advantages Over Conventional Drug Delivery Systems

Modern medicine is undergoing a revolution thanks to nanoparticle-based drug delivery systems. In contrast to conventional medication delivery systems, these small carriers can be customized to accomplish some pretty amazing things, such as improving drug delivery, reducing side effects, and helping patients adhere to their treatment plans. Because of their unique characteristics adaptable architecture, NDDS provide a number of significant benefits over conventional drug delivery methods. The following summarizes what sets them apart:

Enhanced Solubility and Bioavailability

Many medications, particularly those that are poorly soluble in water, have trouble being absorbed by the body, which inhibits their effectiveness. This issue can be resolved by using nanoparticles to encapsulate these difficult-to-dissolve medications and make them more soluble. As a result, the body may more easily absorb the medication and deliver it to its intended location. Solid lipid and polymer-based nanoparticles, for instance, have been demonstrated to greatly increase the solubility and efficacy of these difficult-to-deliver medications, improving treatment outcomes overall.

Controlled and Sustained Drug Release

One of the main advantages of systems based on nanoparticles is their capacity to distribute medications gradually and consistently over time. Instead of experiencing the highs and lows that typically accompany frequent dosing, the drug remains at the ideal level in the body for a longer period of time. This makes it easier for patients to adhere to therapy because they don't have to take their medication as frequently. Drugs can be released gradually using nanoparticles made of materials like PLGA, for example, improving outcomes and reducing side effects.

Targeted Drug Delivery

Nanoparticles can be engineered to locate and adhere to particular bodily cells, resembling a lock-and-key mechanism. Target cells, including cancer cells, can be actively sought out and bound by them by attaching chemicals like peptides or antibodies to their surface. Because of this, more of the medication reaches the precise location where it is needed and less of it damages healthy tissues. What was the outcome? better effective treatment with fewer adverse effects. In cancer treatment, this type of tailored approach is particularly helpful since it helps administer chemotherapy medications directly to tumor cells while preserving the body's other tissues.

Reduced Side Effects and Toxicity

One of the main advantages of employing nanoparticles to deliver drugs is that they can help prevent the unintended side effects that potent treatments frequently have. These mechanisms restrict the amount of the medicine that reaches healthy areas of the body by delivering it straight to the sick location and regulating its release. This translates to better treatment outcomes, fewer side effects, and a more comfortable experience for patients, particularly during intensive therapies like chemotherapy.

Ability to Cross Biological Barriers

Most medications have a very difficult time passing through certain regions of the body, such as the brain, which are shielded by strong barriers. For instance, many drugs cannot pass across the blood-brain barrier (BBB) to the brain, making it particularly challenging to treat diseases like Alzheimer's or brain tumors. However, nanoparticles are able to evade these defenses because of their small size and unique surface patterns. This creates new opportunities for bringing therapies to previously unreachable locations, particularly for illnesses of the brain and nervous system.

Improved Stability and Protection of Therapeutics

Nanoparticles protect medications from substances in the body that could cause them to degrade too quickly, such as enzymes or pH fluctuations, by acting as small protective bubbles. This is particularly useful for medications that are readily rendered ineffective before they reach their intended target, such peptides or genetic material. By maintaining these medications' stability and integrity, nanoparticles assist guarantee that they reach the intended location in the body and carry out their intended function.

Multifunctionality and Theranostic Applications

Nanoparticle drug delivery systems are amazing because they can do more than just deliver medication. In a concept known as theranostics, they can be made to both help with diagnosis and provide treatment. A cancer medication plus an imaging agent, for instance, may be carried by a single nanoparticle, giving medical professionals real-time tracking of the drug's location and effectiveness. Treatment plans that are more precisely customized for each patient are supported by this type of all-in-one method.

Applications in Pharmacy

Uses in Medicine The treatment of various diseases has changed as a result of nanoparticle- based drug delivery systems (NDDS). These small carriers have created new opportunities in modern pharmacy by enhancing the way medications function in the body, including their duration, location, and efficacy. They are being utilized in a variety of treatments, ranging from conveying genetic material to treating brain diseases and infections to combating cancer. Some of the most significant applications of nanoparticles in the pharmaceutical industry are listed below.

Cancer Therapy: Targeted Chemotherapy

Targeted chemotherapy is one of the most well-known applications of nanoparticle medication delivery in cancer treatment. Because it targets healthy cells in addition to cancerous ones, traditional chemotherapy can have a negative impact on the entire body and produce numerous side effects. This is resolved by nanoparticles, which deliver the medication straight to cancer cells while largely sparing healthy tissue. Examples from the real world include FDA-approved drugs Abraxane (paclitaxel coupled to albumin nanoparticles) and Doxil (a liposomal version of doxorubicin). These new formulations increase the amount of the medicine that actually reaches the tumor, prolong its half-life in the bloodstream, and drastically cut down on dangerous side effects like low white blood cell counts and heart damage [18].

Antimicrobial Applications: Enhanced Penetration and Action

Improved Action and Penetration The battle against infections is also being significantly aided by nanoparticles, particularly in the battle against drug-resistant bacteria and obstinate biofilms. Some nanoparticles have potent antibacterial qualities, such as those derived from copper, gold, or silver. They prevent biofilms from developing, break down bacterial membranes, and improve the penetration of antibiotics [19]. Particularly, silver nanoparticles are already being used in products such as lotions, wound dressings, and medical device coatings due to their capacity to eradicate microorganisms and accelerate the healing process.

Neurological Disorders: Blood-Brain Barrier Penetration

Penetration of the Blood-Brain Barrier It is extremely difficult to treat brain-related disorders like Alzheimer's, Parkinson's, or brain cancers since most medications cannot pass across the blood-brain barrier (BBB), which is the brain's natural defense. That is changing with the aid of nanoparticles. These tiny carriers have the ability to bypass the blood-brain barrier and deliver medication straight to the brain when they are engineered with particular targeting molecules. Formulations like liposomes and PLGA-based polymeric nanoparticles are frequently employed to deliver medications like dopamine (for Parkinson's disease) or anti- inflammatory medicines meant to slow down neurodegeneration [20]. These delivery methods increase the total therapeutic efficacy by preventing the medicine from degrading too quickly and ensuring that more of it reaches the brain where it is needed.

Vaccines and Gene Delivery: mRNA and DNA-Based Systems

Gene Delivery and Vaccines: Systems Based on mRNA and DNA Since they can transport genetic material like DNA and RNA, nanoparticles have emerged as important players in the fields of gene therapy and vaccinations. The recent success of mRNA vaccines against COVID-19 is a prime illustration of their influence. Both the Pfizer-BioNTech and Moderna vaccines used lipid nanoparticles (LNPs) to deliver the mRNA safely into cells [21]. These nanoparticles facilitate the entry of the delicate mRNA into cells, prevent it from degrading too quickly, and guarantee that the body can make the appropriate proteins to elicit an immune response. By delivering therapeutic genes directly to cells, similar systems are being investigated to treat genetic disorders and other diseases in addition to vaccines.

Apart from lipid nanoparticles, other gene delivery systems under investigation include polymeric nanoparticles and dendrimers, which can safely transport genetic material into cells, paving the way for cutting-edge treatments like gene editing or gene silencing. This holds great promise for treating hereditary diseases like Duchenne muscular dystrophy and cystic fibrosis, where repairing or shutting off defective genes could significantly improve patient outcomes [22].

Oral, Ocular, and Transdermal Drug Delivery

Drug Delivery via Oral, Ocular, and Transdermal Additionally, drug distribution through the mouth, eyes, and skin is becoming simpler and more efficient thanks to nanoparticles. Options such as lipid-based nanoparticles or nanocrystals can improve the stability and solubility of medications that often don't dissolve well in water when taken orally. Better outcomes are achieved as a result of their easier absorption through the digestive tract [23].

Nanoparticles like micelles and liposomes aid in the transdermal distribution of drugs by allowing them to pass through the epidermis' outermost layer and penetrate deeper tissues or even the circulation. Compared to tablets or injections, this method is particularly helpful for medications that relieve pain or inflammation because it is non-invasive [23].

Commercial Products and Clinical Trials

Consumer Goods and Research Studies Nanoparticle-based drug delivery systems, or NDDS, have entered the field of medicine and are no longer merely a theoretical idea. A number of laboratory-developed formulations have made it into clinical use; some have received FDA approval, while others are shown promising results in current clinical trials. These developments demonstrate that NDDS are useful for routine healthcare in addition to being safe and effective. This section will examine a few well-known, authorized products based on nanoparticles and discuss how clinical trials are extending their use in several therapeutic domains.

FDA-Approved Nanoparticle-Based Formulations

FDA-Approved Formulations Using Nanoparticles Numerous medication delivery methods based on nanoparticles have advanced through the development process and been approved by the FDA to treat a range of illnesses. These products frequently provide significant benefits over conventional medications, such as longer half-lives, more accurate medication delivery, and fewer adverse effects. Their achievements demonstrate how nanotechnology is assisting in the translation of cutting-edge research into practical, efficient therapies that are already enhancing patient care.

Doxil (Liposomal Doxorubicin)

Liposome-based doxorubicin, or Doxil One of the first and most well-known achievements in the treatment of cancer with nanoparticles is Doxil. This medication is a liposomal form of the potent chemotherapeutic chemical doxorubicin. Doxil helps shield healthy tissues— particularly the heart— from the severe side effects that typically accompany doxorubicin by encapsulating the medication inside small liposomes. By means of the Enhanced Permeability and Retention (EPR) effect, the liposomes additionally aid in the drug's prolonged circulation and improved accumulation at tumor locations [24]. Doxil, which has FDA approval for the treatment of breast cancer, ovarian cancer, and Kaposi's sarcoma, is a prime illustration of how nanomedicine can enhance cancer treatment's efficacy and safety.

Abraxane (Albumin-Bound Paclitaxel)

(Albumin-Bound Paclitaxel) Abraxane Another notable product in the field of medication delivery using nanoparticles is Abraxane. It is a type of the chemotherapy medication paclitaxel, but rather than dissolving in harsh solvents as in conventional formulations, it is attached to microscopic albumin particles, which are naturally occurring proteins in the body. Because of this ingenious design, hazardous solvents are no longer necessary, which reduces patient discomfort and allergic responses.

Onpattro (siRNA-Loaded Lipid Nanoparticle)

Lipid nanoparticles loaded with siRNA are called Onpattro. Using lipid nanoparticles, Onpattro (patisiran) was the first FDA-approved medication to use RNA interference (RNAi) technology. Sheeditary transthyretin-mediated amyloidosis is an uncommon and progressive illness that affects the nerves and other organs. The drug works by using small interfering RNA (siRNA) to silence the transthyretin gene, which is faulty and causes harmful protein buildup. In order to shield siRNA—which is sensitive and easily broken down by the body— and deliver it straight to the liver cells.

Ongoing Clinical Trials and Pipeline Products

Continuous Clinical Research and Pipeline Items There are numerous medications based on nanoparticles that are currently licensed and in use, but many more are being developed.

New formulations are being tested in ongoing clinical trials to determine how well they can enhance drug delivery and increase the number of treatment choices available for various illnesses. In order to make nanoparticles even more safe, effective, and targeted, researchers are trying to improve their behavior within the body.

Nanoparticle-Based Vaccines

Vaccines Using Nanoparticles Since the COVID-19 pandemic, vaccinations based on nanoparticles have gained a lot of attention. The mRNA employed in the Pfizer-BioNTech and Moderna vaccines was primarily delivered by lipid nanoparticles (LNPs). These microscopic transporters ensured that the delicate mRNA reached the appropriate cells to elicit a potent immune response while also protecting it. Building on this achievement, research is currently being done in clinical trials to see if LNPs may be incorporated into vaccines against HIV, cancer, and influenza. To get closer to the next generation of vaccinations, the objective is to develop vaccines that are more stable, efficient, and simple to administer [25].

Nanoparticle-Based Gene Therapies

Nanoparticles are opening exciting new doors in the world of gene therapy. Researchers are exploring their use to treat a range of genetic disorders like cystic fibrosis, Duchenne muscular dystrophy, and hemophilia. By using nanoparticles—made from materials like lipids, polymers, or dendrimers—scientists can safely deliver therapeutic genes right into specific cells or tissues. The goal is to fix faulty genes, add new ones that help fight disease, or switch off genes that are causing harm. Several of these approaches are currently being tested in clinical trials, offering hope for long-term solutions to conditions that were once considered untreatable [26].

Targeted Nanoparticle-Based Drug Delivery in Cancer

Targeted Drug Delivery in Cancer Using Nanoparticles The potential of tailored nanoparticles to enhance chemotherapy delivery to tumors is being intensively studied in clinical trials. Different kinds of nanoparticles, such as liposomes, micelles, and dendrimers, that are intended to locate cancer cells utilizing targeting ligands are being tested in these trials. For instance, some trials are treating HER2-positive breast cancer using nanoparticles that directly bind to HER2 receptors, while other trials are treating prostate cancer with PSMA-targeted nanoparticles. The goal is to increase the efficiency of chemotherapy medications while lowering their negative side effects by delivering them more directly to cancer cells [27].

Toxicological concerns and safety issues:

While nanoparticle-based drug delivery systems (NDDS) offer exciting potential to make treatments more effective, they also raise important safety questions. Because of their tiny size and how they interact with the body, nanoparticles can behave very differently from regular drug materials. This means we need to carefully look at possible risks—like toxicity to cells, buildup in organs, how the body reacts to them, and whether they're safe in the long run—before they can be used widely in patients.

Cytotoxicity and Oxidative Stress:

Overstress and Cytotoxicity, or the potential for nanoparticles to damage healthy cells, is one of the main safety concerns. Through the production of reactive oxygen species (ROS), some nanoparticles can cause oxidative stress in cells [28]. According to, this oxidative stress can interfere with mitochondrial activity, damage cell membranes, and even damage DNA. Size, shape, surface charge, and general design are some of the variables that influence how nanoparticles impact cells. nanoparticles throughout their development, particularly if they will be applied to medical applications. This guarantees that they are safe for patients over the long run in addition to being effective.

Compared to other varieties, metal-based nanoparticles, such as those derived from silver, are especially known to induce higher levels of oxidative stress [29].

Accumulation in Organs and Tissues

Their propensity to accumulate in specific organs, including the liver, spleen, and kidneys, presents a significant obstacle to medication administration using nanoparticles. This occurs as a result of the reticuloendothelial system (RES), which naturally filters and stores these particles to aid in the removal of foreign substances. Although excessive buildup in these organs over time might result in major problems like fibrosis, inflammation, or even organ destruction, this process is natural [30]. Controlling how nanoparticles react in the body is crucial because of this. How they are altered, their size, and surface characteristics all affect where they end up and how long they remain there.

Biocompatibility and Biodegradability

The features of biodegradability and biocompatibility A primary concern in the use of nanoparticles in medicine is safety, which begins with the particles' compatibility with the body. In this case, biocompatibility is important. It describes the safe way in which nanoparticles can engage with our biological systems without causing negative side effects. The charge, hydrophobicity (the ability to attract or repel water), and chemical groups on the surface of the nanoparticle all play a significant role in this. Inadequately engineered surfaces have the potential to trigger immunological reactions, which over time may result in inflammation or even tissue damage [31].

Additionally, biodegradability is crucial. The goal is to have nanoparticles that the body can safely break down and get rid of. Long-term problems could arise if they remain in tissues and are not biodegradable or decompose too slowly. Even so, it is necessary to evaluate those breakdown products to ensure that they do not cause issues on their own.

Long-Term Safety Studies

It's critical to investigate the long-term safety of nanoparticle-based medication delivery systems because they are still a relatively new development. Particularly in clinical and preclinical investigations, the majority of current research tends to concentrate on short-term impacts. When the body is exposed to nanoparticles for prolonged periods of time, however, chronic exposure may have rather distinct effects. The development of cancer, tissue scarring (fibrosis), or even an unintentional immune system activation are possible dangers [32].

Regulatory Framework for Safety Assessment

Regulatory agencies including the FDA, European Medicines Agency (EMA), and International Council for Harmonization (ICH) have established stringent rules for assessing the safety of nanomedicines due to the distinct properties—and possible hazards—of nanoparticles. These rules encompass everything from the characterization of nanoparticles to the evaluation of their toxicity, pharmacokinetic and pharmacodynamic activity within the body, and immunological reactions [33].

Regulatory and Quality Control Aspects

Quality Control and Regulatory Aspects Nanoparticle-based drug delivery systems (NDDS) must pass stringent quality control and regulatory scrutiny before they can be sold. Taking these actions is crucial to ensuring that each product is consistently produced to satisfy high standards of quality, in addition to being safe and effective. All facets of NDDS development, from formulation to testing and production, are meticulously assessed and managed with the aid of regulatory frameworks.

Regulatory Guidelines for Nanomedicine

Regulation of Nanomedicines Before being licensed for clinical use, nanomedicines—

including nanoparticle-based drug delivery systems (NDDS)—must adhere to stringent regulatory requirements. Prior to being administered to patients, these rules aid in ensuring that nanomedicines are regularly produced and subjected to extensive testing.

Crucial Phases of the NDDS Regulatory Review To guarantee that medication delivery systems based on nanoparticles are both safe and efficient for patient usage, the regulatory approval procedure entails many crucial steps:

Preclinical Evaluation: Nanoparticles are subjected to both in vitro (lab-based) and in vivo (animal) tests prior to human testing. These aid in evaluating the toxicity, absorption and distribution patterns, and duration of the

particles' presence in the body.

- Clinical studies: Nanomedicines must successfully complete demanding Phase I, II, and III clinical studies, much like any other new medication. These studies assess anything from short-term safety in small groups to long-term efficacy and adverse effects in bigger populations.

Post-Market Surveillance: The work doesn't end when a product is put on the market. Its performance is continuously monitored by regulatory bodies in order to identify any uncommon or persistent problems that might not have surfaced during clinical trials.

Quality Control and Standardization of Nanoparticles

Controlling Quality and Standardizing Nanoparticles Quality control guarantees the safety, efficacy, and consistency of medications based on nanoparticles. An analysis of nanoparticles Predicting the behavior of nanoparticles in the body requires an understanding of critical characteristics such as size, shape, and surface charge.

Characterization of Nanoparticles

A comprehensive understanding of the physicochemical properties of nanoparticles is essential for ensuring their safety and efficacy.

Size and Size Distribution: * Size & Distribution: The size of nanoparticles influences their absorption capacity, circulation duration, and tissue penetration depth.

- Surface charge, also known as zeta potential, controls stability and the way that nanoparticles engage with cells. Additionally, it aids in immunological clearance prediction.
- Surface Functionalization: Enhancing targeting and minimizing adverse effects can be achieved by altering the surface of nanoparticles

Manufacturing Process Control

Control of Manufacturing Activities To guarantee constant quality, the manufacturing process of nanoparticle formulations needs to be closely regulated. Among the crucial elements of the production process are

Nanoparticle Synthesis Emulsification, nanoprecipitation, and solvent evaporation are often employed techniques for creating nanoparticles. Optimizing the synthesis process is necessary to guarantee that the nanoparticles have the appropriate size, surface characteristics, and encapsulation effectiveness.

Sterility and Endotoxin Testing It is essential that injectable nanoparticles are sterile and devoid of dangerous poisons. Sterility is guaranteed by filtering, and safety is verified by measuring endotoxin levels using the LAL test.

Stability Testing: Testing for Stability Testing for stability ensures that nanoparticles remain secure and efficient throughout time. It entails keeping an eye on variations in various storage settings, such as humidity, light, and heat.

Scaling Up Production

Growing Production The creation of nanoparticles is difficult to scale up from laboratory to commercial levels. To achieve regulatory requirements, it necessitates high yields, rigorous adherence to Good Manufacturing Practice (GMP) standards, and uniform quality across batches.

Challenges in Regulatory Approval of Nanomedicines

Regulatory Approval Obstacles for Nanomedicines Nano medicines' regulatory approval procedure is still developing, and there are still a number of obstacles to overcome:

Lack of Standardized Testing Protocols Since every type of nanoparticle behaves differently, there is no one-size-fits-all method for testing them. This slows down development and approval by making it difficult to establish a single, unambiguous regulatory path Complexity of Nanoparticle Behavior: In contrast to conventional medications, nanoparticles behave differently in the body. Their distinct interactions make it more difficult to forecast their behavior, which complicates testing and approval.

Public Perception and Ethical Concerns: People may be concerned about the environmental impact and safety of nanoparticles. In order to ensure responsible use, regulators must address ethical concerns and public trust.

Future Trends and Challenges

Because of scientific and technological advancements, the use of nanoparticles for medication delivery is expanding quickly. Despite the enormous potential of these systems, there are still obstacles to overcome, such as improving designs, obtaining regulatory approval, and transitioning from lab to clinic. Future developments include the application of AI, the development of multipurpose nanoparticles, and personalized medicine, which allows for the customization of specific treatments.

Personalized Nanomedicine

Personalized nanomedicine, which involves tailoring therapies according to an individual's biology and genetics, is a significant emerging concept in drug delivery. By targeting certain illness characteristics, such as genetic abnormalities or tumor microenvironment, nanoparticles can be engineered to improve the precision and efficacy of treatments for each patient.

Multifunctional and Hybrid Nanoparticles

Using multifunctional or hybrid nanoparticles, which are capable of more than just drug delivery, is becoming more and more popular in NDDS. These smart technologies can also aid in diagnostic and imaging, allowing for simultaneous monitoring and treatment of diseases like cancer. This "theranostic" method promotes more effective and individualized treatment.

Artificial Intelligence (AI)-Integrated Nanotechnolog

This revolutionary approach to drug delivery combines nanotechnology and artificial intelligence. AI can speed up the development process, assist in designing and optimizing nanoparticles, and forecast how they will behave in the body, all of which can result in more intelligent and efficient treatments.

Difficulties in Commercialization and Scaling Up:

Although NDDS have a lot of potential, a significant obstacle is getting from laboratory to large-scale production. Most techniques for creating nanoparticles are effective in the lab but difficult to scale up. At the business level, maintaining quality, consistency, and compliance with regulations is still quite difficult.

Ethical and Environmental Considerations

As nanoparticles are used more often in medicine, worries about their long-term effects on the environment are mounting. Ecosystems may become overpopulated with non-biodegradable nanoparticles, endangering species and the environment. In order to maintain sustainability and public confidence, ethical manufacturing, usage, and disposal methods are essential.

CONCLUSION

In conclusion, by tackling important issues like low solubility and non-specific targeting, nanoparticles are revolutionizing medicine delivery in the future. They provide more intelligent, efficient treatment alternatives by improving drug performance and decreasing side effects through their adjustable size and surface characteristics. Their contribution to precision and personalized medicine will only increase as research advances.

Different nanoparticle kinds, such as carbon-based, dendritic, metallic, polymeric, and lipid-based, each have special advantages for drug delivery. In order to treat complex ailments like cancer, neurological disorders, and infections, they are particularly useful since they provide focused, regulated, and site-specific treatment. The fact that they can penetrate biological barriers, such the blood-brain barrier, has made previously unattainable treatments possible.

Despite the remarkable advancements in medicine delivery via nanoparticles, there are still issues. Scaling up production while maintaining quality is challenging, standard testing procedures are inadequate, and regulatory systems are slowly catching up.

In the future, cutting-edge developments like smart multifunctional nanoparticles, tailored nanomedicine, and the use of AI to drug delivery system design may revolutionize the way we treat illnesses. With "theragnostic," diagnosis and treatment are merged into a single nanoparticle, providing a more accurate and efficient method of care.

It's crucial to remember the ethical, environmental, and public concerns related to nanomedicine despite all of these wonderful advancements. As we proceed responsibly, we must ensure that nanoparticles are environmentally benign, safe for the body, and decompose organically. Achieving these goals is essential to sustainable development.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Crommelin, D. J. A., & Florence, A. T. Towards more effective advanced drug delivery systems. International Journal of Pharmaceutics, 2013;454(1):496–511.DOI: 10.1016/j.ijpharm.2013.04.050 PMID: 23608610

2. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology & Therapeutics, 2008;83(5):761–769. DOI: 10.1038/sj.clpt.6100400 PMID: 17957183

3. Barenholz, Y. Doxil—the first FDA-approved nano-drug: lessons learned. Journal of Controlled Release, 2012;160(2):117–134. DOI: 10.1016/j.jconrel.2012.03.020 PMID: 22484195

4. Bozzuto, G., & Molinari, A. Liposomes as nanomedical devices. International Journal of Nanomedicine, 2015;10:975–999. DOI: 10.2147/IJN.S68861 PMID: 25678787 PMCID: PMC4324542

5. Bozzuto, G., & Molinari, A.. Liposomes as nanomedical devices. International Journal of Nanomedicine, 2015;10:975–999.

6. Sogias, I. A., Khutoryanskiy, V. V., & Williams, A. C. Exploring the factors affecting the solubility of chitosan in water. Macromolecular Chemistry and Physics, 2008;209(14):1473–1480. DOI: 10.1002/macp.200800122

7. Dreaden, E. C., Mackey, M. A., Huang, X., Kang, B., & El-Sayed, M. A. Beating cancer in multiple ways using nanogold. Chemical Society Reviews, 2012;40(7):3391–3404. DOI: 10.1039/c0cs00180e PMID: 21629885 PMCID: PMC5875987

8. Franci, G., Falanga, A., Galdiero, S., Palomba, L., Rai, M., Morelli, G., & Galdiero, M. Silver nanoparticles as potential antibacterial agents. Molecules, 2015;20(5):8856–8874. DOI: 10.3390/molecules20058856 PMID: 25993417 PMCID: PMC6272636

9. Gupta, A. K., & Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005;26(18):3995–4021. DOI: 10.1016/j.biomaterials.2004.10.012 PMID: 15626447

10. Kesharwani, P., Jain, K., & Jain, N. K. Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science, 2014;39(2),268–307.DOI: 10.1016/j.progpolymsci.2013.07.005

11. Kataoka, K., Harada, A., & Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Advanced Drug Delivery Reviews, 2001;47(1):113–131. DOI: [10.1016/S0169-409X(00)00124-1]

12. Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., & Liang, X. J. pH- sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances, 2014;32(4):693–710.

13. Bae, Y., Fukushima, S., Harada, A., & Kataoka, K. Design of environment- sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angewandte Chemie International Edition, 2003;42(38):4640–4643. DOI: 10.1002/anie.200250653 PMID: 14533151

14. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 2000;65(1–

2):271–284. DOI: 10.1016/S0168-3659(99)00248-5 PMID: 10699287

15. Mieszawska, A. J., Mulder, W. J. M., Fayad, Z. A., & Cormode, D. P. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Molecular Pharmaceutics, 2013;10(3):831–847. DOI: 10.1021/mp300546e PMID: 23360440

16. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 2012;161(2):505–522. DOI: 10.1016/j.jconrel.2012.01.043 PMID: 22353619

17. Torchilin, V. P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nature Reviews Drug Discovery, 2014;13(11):813–827. DOI: 10.1038/nrd4333 PMID: 25287120 PMCID: PMC4489143

18. Silverman, J. A., & Kester, M. Doxil: A nanoformulation of doxorubicin for the treatment of cancer. Expert Opinion on Drug Delivery, 2010;7(5):679–687. DOI: 10.1517/17425241003674349 PMID: 20415567

19. Arias, C. A., & Murray, B. E. Antibiotic-resistant bugs in the 21st century—A clinical super-challenge. New England Journal of Medicine, 2009;360(5):439–443. DOI: 10.1056/NEJMp0804651 PMID: 19179315

20. Barzegar, S., Baghery, S., & Ghoreishi, S. M. Nanoparticle-based delivery of anti- inflammatory drugs for treatment of neurodegenerative diseases. Biomaterials Science, 2019;7(3):1424–1437 DOI:10.1039/C8BM01219A PMID: 30707092

21. Pardi, N., Hogan, M. J., & Porter, F. W. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 2018;17(4):261–279. DOI: 10.1038/nrd.2017.243 PMID: 29326426 PMCID: PMC5906799

22. Seyedmajidi, M., Ghanbari, H., & Zeynizadeh, B. Gene delivery to targeted cells using nanoparticle systems. Nanotechnology Reviews, 2016;5(3):257–276 DOI: 10.1515/ntrev-2016-0016

23. Luo, Y., Liu, C., & Zhang, Q. Recent advances in nanoparticle-based drug delivery systems for oral drug delivery. International Journal of Pharmaceutics, 2020;587(1):119670. DOI: 10.1016/j.ijpharm.2020.119670 PMID: 32061889

24. Allen, T. M., & Cullis, P. R. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 2013;65(1):36–48. DOI: 10.1016/j.addr.2012.09.037 PMID: 23036345

25. Mignatti, P., Taraboletti, G., & Rabinovich, G. Nanoparticle albumin-bound paclitaxel in cancer therapy. Cancer Treatment Reviews, 2015;41(1):39–46. DOI: 10.1016/j.ctrv.2014.10.001 PMID: 25455458

26. Pardi, N., Hogan, M. J., & Porter, F. W. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 2018;17(4): 261–279. DOI: 10.1038/nrd.2017.243 PMID: 29326426 PMCID: PMC5906799

27. Kumar, P., Sinha, S., & Pandey, R. Nanoparticle-based gene delivery systems in clinical applications. Molecular Therapy - Methods & Clinical Development, 2020;18:1–17. DOI: 10.1016/j.omtm.2020.05.003 PMID: 32518736 PMCID: PMC7279934

28. Mikhail, S. H., El-Khoueiry, A. B., & Liu, H. Targeted nanoparticle therapy in solid tumors. Cancer Research, 2020;80(18):3960–3969. DOI: 10.1158/0008-5472.CAN-20-1234 PMID: 32719146

29. Sharma, V., Singhal, G., & Mehra, N. K. Nanoparticles in drug delivery: Their toxicological effects and safety concerns. Journal of Nanoscience and Nanotechnology, 2012;12(7):5079–5085. DOI: 10.1166/jnn.2012.6162 PMID: 22905517

30. AshaRani, P. V., Mun, G. H., & Hande, M. P. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano, 2009;3(5):2775–2781.

31. Cojocaru, F., Blanck, M., & Sadovska, M. Toxicology of nanoparticle-based drug delivery systems. Nanotoxicology, 2019;13(3):313–327.

32. Yin, J. J., & Wang, D. Biocompatibility and biodegradability of nanoparticles. Materials Science and Engineering: C, 2014;39:224–235.